Related references
Note: Only part of the references are listed.The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK plus anaplastic large cell lymphoma
Vassilis Atsaves et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma
Vasiliki Leventaki et al.
HUMAN PATHOLOGY (2014)
JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles
Anthony Mathelier et al.
NUCLEIC ACIDS RESEARCH (2014)
Association of Toxicity of Sorafenib and Sunitinib for Human Keratinocytes with Inhibition of Signal Transduction and Activator of Transcription 3 (STAT3)
Kazuhiro Yamamoto et al.
PLOS ONE (2014)
Evaluation of STAT3 Signaling in ALDH plus and ALDH+/CD44+/CD24-Subpopulations of Breast Cancer Cells
Li Lin et al.
PLOS ONE (2013)
Ets-1 Activates Overexpression of JunB and CD30 in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma
Mariko Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126
M. Ito et al.
CANCER GENE THERAPY (2010)
Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair
L. Tian et al.
ONCOGENE (2010)
An attractive therapeutic target, mTOR pathway, in ALK plus anaplastic large cell lymphoma
Jeong Hee Cho-Vega et al.
ADVANCES IN ANATOMIC PATHOLOGY (2008)
Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1α is essential for cytokine-driven C-reactive protein gene expression
Teppei Nishikawa et al.
JOURNAL OF IMMUNOLOGY (2008)
Hypomethylation of CD30 CpG islands with aberrant JunB expression drives CD30 induction in Hodgkin lymphoma and anaplastic large cell lymphoma
Mariko Watanabe et al.
LABORATORY INVESTIGATION (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling
Philipp B. Staber et al.
BLOOD (2007)
NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma
Vasiliki Leventaki et al.
BLOOD (2007)
Upregulation of AKT1 protein expression in forskolin-stimulated macrophage: Evidence from ChIP analysis that CREB binds to and activates the AKT1 promoter
Uma Kant Misra et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Amino acid residues required for physical and cooperative transcriptional interaction of STAT3 and AP-1 proteins c-jun and c-fos
Michael Ginsberg et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
c-Jun expression and activation are restricted to CD30(+) lymphoproliferative disorders
Elias Drakos et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Stattic: A small-molecule inhibitor of STAT3 activation and dimerization
Jochen Schust et al.
CHEMISTRY & BIOLOGY (2006)
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
Francisco Vega et al.
CANCER RESEARCH (2006)
Protocol for the fast chromatin immunoprecipitation (ChIP) method
Joel D. Nelson et al.
NATURE PROTOCOLS (2006)
Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas
GC Fillmore et al.
LEUKEMIA & LYMPHOMA (2005)
Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway
S Park et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
Regulation of the Akt kinase by interacting proteins
KY Du et al.
ONCOGENE (2005)
JunB expression is a common feature of CD30+lymphomas and lymphomatoid papulosis
GZ Rassidakis et al.
MODERN PATHOLOGY (2005)
Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells
S Dihlmann et al.
CARCINOGENESIS (2005)
Inhibition of Akt increases P27KiP1 levels and induces cell cycle arrest in anaplastic large cell lymphoma
GZ Rassidakis et al.
BLOOD (2005)
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
HG Wendel et al.
NATURE (2004)
Transcriptional regulation of AKT activation by E2F
M Chaussepied et al.
MOLECULAR CELL (2004)
Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma
HM Amin et al.
ONCOGENE (2003)
JunB gene expression is inactivated by methylation in chronic myeloid leukemia
MY Yang et al.
BLOOD (2003)
Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells
H Ruchatz et al.
EXPERIMENTAL HEMATOLOGY (2003)
Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB
S Mathas et al.
EMBO JOURNAL (2002)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
AP-1 as a regulator of cell life and death
E Shaulian et al.
NATURE CELL BIOLOGY (2002)
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death
A Zamo et al.
ONCOGENE (2002)
Translocations involving anaplastic lymphoma kinase (ALK)
J Duyster et al.
ONCOGENE (2001)
c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 response element (IRE)
JJ Schuringa et al.
CYTOKINE (2001)
Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking JunB expression in the myeloid lineage
E Passegué et al.
CELL (2001)
JunB suppresses cell proliferation by transcriptional activation of p16INK4a expression
E Passegué et al.
EMBO JOURNAL (2000)
Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression
L Bakiri et al.
EMBO JOURNAL (2000)
Share Paper
